{"title":"益生菌豆浆对2型糖尿病肾病患者脂质面板的影响:一项双盲随机临床试验","authors":"B. Abbasi, M. Mirlohi, M. Daniali, R. Ghiasvand","doi":"10.23751/PN.V20I2-S.5342","DOIUrl":null,"url":null,"abstract":"Background: Cardiovascular diseases (CVD) are among the most common complications of diabetes. Lipid abnormalities in diabetic patients are not only related to higher risk of CVD, but also accelerate the progression of diabetic nephropathy. To the best of our knowledge, there is no study that has assessed the effects of probiotic soy milk on lipid profile in type 2 diabetic patients with nephropathy. Objective: The current study was designed to examine the effects of consumption of soy milk containing lactobacillus plantarum A7 compared with conventional soy milk on lipid panel in type 2 diabetic patients with nephropathy. Methods: A total of 44 type 2 diabetic patients with nephropathy were randomly assigned to receive 200 ml/day of either probiotic soy milk (n=22) or conventional soy milk (n=22) for eight weeks, in this randomized double-blind clinical trial. Fasting blood samples were taken at the beginning and after eight weeks of the intervention for analysis of lipid profile and other relevant variables. P values < 0.05 were considered as statistically significant. Results: Consumption of probiotic soy milk for 8 weeks led to an increase in serum genistein (17.6±15.3 vs. 4.5±2.3, p=0.002) and eGFR (15.9±10.8 vs. 3.2±8.4, p<0.001) compared with conventional soy milk. Additionally probiotic soy milk resulted in decreased LDL-cholesterol (-9.2±10.4 vs. -2.2±5.2, p=0.01), total cholesterol (-12.4±4.8 vs. -4.87±14.7, p=0.04), non-HDL cholesterol (-15.3±4.5 vs. -5.9±14.7, p=0.01) and serum TG (-14.6±12.5 vs. -3.9±9.3, p=0.007) compared with control group. We did not detect any significant effect of probiotic soy milk on serum HDL-cholestrol (1.11±3.38 vs. 0.90±2.7, p=0.8) and serum phosphorus (-0.14±0.10 vs. 0.05±0.5, p=0.1). Conclusion: Administration of soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy had beneficial effects on lipid profile and glomerular function, but did not affect HDL-cholesterol. In addition probiotic soy milk did not result in a significant elevation in the serum phosphorus concentration. This trial was registered at http://www.irct.ir as IRCT201601027479N2.","PeriodicalId":20600,"journal":{"name":"Progress in Nutrition","volume":"20 1","pages":"70-78"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":"{\"title\":\"Effects of probiotic soy milk on lipid panel in type 2 diabetic patients with nephropathy: A double-blind randomized clinical trial\",\"authors\":\"B. Abbasi, M. Mirlohi, M. Daniali, R. Ghiasvand\",\"doi\":\"10.23751/PN.V20I2-S.5342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Cardiovascular diseases (CVD) are among the most common complications of diabetes. Lipid abnormalities in diabetic patients are not only related to higher risk of CVD, but also accelerate the progression of diabetic nephropathy. To the best of our knowledge, there is no study that has assessed the effects of probiotic soy milk on lipid profile in type 2 diabetic patients with nephropathy. Objective: The current study was designed to examine the effects of consumption of soy milk containing lactobacillus plantarum A7 compared with conventional soy milk on lipid panel in type 2 diabetic patients with nephropathy. Methods: A total of 44 type 2 diabetic patients with nephropathy were randomly assigned to receive 200 ml/day of either probiotic soy milk (n=22) or conventional soy milk (n=22) for eight weeks, in this randomized double-blind clinical trial. Fasting blood samples were taken at the beginning and after eight weeks of the intervention for analysis of lipid profile and other relevant variables. P values < 0.05 were considered as statistically significant. Results: Consumption of probiotic soy milk for 8 weeks led to an increase in serum genistein (17.6±15.3 vs. 4.5±2.3, p=0.002) and eGFR (15.9±10.8 vs. 3.2±8.4, p<0.001) compared with conventional soy milk. Additionally probiotic soy milk resulted in decreased LDL-cholesterol (-9.2±10.4 vs. -2.2±5.2, p=0.01), total cholesterol (-12.4±4.8 vs. -4.87±14.7, p=0.04), non-HDL cholesterol (-15.3±4.5 vs. -5.9±14.7, p=0.01) and serum TG (-14.6±12.5 vs. -3.9±9.3, p=0.007) compared with control group. We did not detect any significant effect of probiotic soy milk on serum HDL-cholestrol (1.11±3.38 vs. 0.90±2.7, p=0.8) and serum phosphorus (-0.14±0.10 vs. 0.05±0.5, p=0.1). Conclusion: Administration of soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy had beneficial effects on lipid profile and glomerular function, but did not affect HDL-cholesterol. In addition probiotic soy milk did not result in a significant elevation in the serum phosphorus concentration. This trial was registered at http://www.irct.ir as IRCT201601027479N2.\",\"PeriodicalId\":20600,\"journal\":{\"name\":\"Progress in Nutrition\",\"volume\":\"20 1\",\"pages\":\"70-78\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"11\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Nutrition\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.23751/PN.V20I2-S.5342\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Agricultural and Biological Sciences\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Nutrition","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23751/PN.V20I2-S.5342","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}
引用次数: 11
摘要
背景:心血管疾病是糖尿病最常见的并发症之一。糖尿病患者血脂异常不仅与CVD发生风险增高有关,而且还会加速糖尿病肾病的进展。据我们所知,目前还没有研究评估益生菌豆浆对2型糖尿病肾病患者血脂的影响。目的:本研究旨在比较食用含有植物乳杆菌A7的豆浆与普通豆浆对2型糖尿病肾病患者脂质面板的影响。方法:在随机双盲临床试验中,44例2型糖尿病肾病患者被随机分配为200 ml/天的益生菌豆浆(n=22)或常规豆浆(n=22),为期8周。在干预开始时和干预八周后采集空腹血样,分析血脂和其他相关变量。P值< 0.05认为有统计学意义。结果:与常规豆浆相比,饮用益生菌豆浆8周后血清染料木素(17.6±15.3比4.5±2.3,p=0.002)和eGFR(15.9±10.8比3.2±8.4,p<0.001)升高。此外,与对照组相比,益生菌豆浆降低了低密度脂蛋白胆固醇(-9.2±10.4比-2.2±5.2,p=0.01)、总胆固醇(-12.4±4.8比-4.87±14.7,p=0.04)、非高密度脂蛋白胆固醇(-15.3±4.5比-5.9±14.7,p=0.01)和血清TG(-14.6±12.5比-3.9±9.3,p=0.007)。我们未发现益生菌豆浆对血清高密度脂蛋白胆固醇(1.11±3.38 vs 0.90±2.7,p=0.8)和血清磷(-0.14±0.10 vs 0.05±0.5,p=0.1)有显著影响。结论:2型糖尿病肾病患者服用植物乳杆菌A7豆浆对其血脂和肾小球功能有改善作用,但对hdl -胆固醇无影响。此外,益生菌豆浆没有导致血清磷浓度的显著升高。该试验在http://www.irct.ir注册,注册号为IRCT201601027479N2。
Effects of probiotic soy milk on lipid panel in type 2 diabetic patients with nephropathy: A double-blind randomized clinical trial
Background: Cardiovascular diseases (CVD) are among the most common complications of diabetes. Lipid abnormalities in diabetic patients are not only related to higher risk of CVD, but also accelerate the progression of diabetic nephropathy. To the best of our knowledge, there is no study that has assessed the effects of probiotic soy milk on lipid profile in type 2 diabetic patients with nephropathy. Objective: The current study was designed to examine the effects of consumption of soy milk containing lactobacillus plantarum A7 compared with conventional soy milk on lipid panel in type 2 diabetic patients with nephropathy. Methods: A total of 44 type 2 diabetic patients with nephropathy were randomly assigned to receive 200 ml/day of either probiotic soy milk (n=22) or conventional soy milk (n=22) for eight weeks, in this randomized double-blind clinical trial. Fasting blood samples were taken at the beginning and after eight weeks of the intervention for analysis of lipid profile and other relevant variables. P values < 0.05 were considered as statistically significant. Results: Consumption of probiotic soy milk for 8 weeks led to an increase in serum genistein (17.6±15.3 vs. 4.5±2.3, p=0.002) and eGFR (15.9±10.8 vs. 3.2±8.4, p<0.001) compared with conventional soy milk. Additionally probiotic soy milk resulted in decreased LDL-cholesterol (-9.2±10.4 vs. -2.2±5.2, p=0.01), total cholesterol (-12.4±4.8 vs. -4.87±14.7, p=0.04), non-HDL cholesterol (-15.3±4.5 vs. -5.9±14.7, p=0.01) and serum TG (-14.6±12.5 vs. -3.9±9.3, p=0.007) compared with control group. We did not detect any significant effect of probiotic soy milk on serum HDL-cholestrol (1.11±3.38 vs. 0.90±2.7, p=0.8) and serum phosphorus (-0.14±0.10 vs. 0.05±0.5, p=0.1). Conclusion: Administration of soy milk containing lactobacillus plantarum A7 in type 2 diabetic patients with nephropathy had beneficial effects on lipid profile and glomerular function, but did not affect HDL-cholesterol. In addition probiotic soy milk did not result in a significant elevation in the serum phosphorus concentration. This trial was registered at http://www.irct.ir as IRCT201601027479N2.
期刊介绍:
Progress in Nutrition was founded in 1999 as an independent magazine, a multidisciplinary approach, dedicated to issues of nutrition and metabolism.